CSTL
Castle Biosciences Inc Health Care Services-Medical Laboratories Russell 3000
$37.16Close
$1.1BMarket cap
$18.15 – $43.0452-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 84 · stronger than 84% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · 150-day under the 200-day, 200-day not rising
- Earnings shrinking EPS −144% year on year
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
14%
1wk
up 12.3%
price change
1mo
up 4.6%
price change
12-month return
up 53%
market up 11% ·
its own up 46%
F-score
3 / 9
Weak
Altman Z″
6.15
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.3×
price / book
Earnings yield
down 4.3%
EBIT / enterprise value
Cheaper than
40%
of the market · around average
Revenue growth
up 4%
year on year
EPS growth
down 144%
latest quarter
Sales growth
up 20%
latest quarter · +25 pts
ROE
down 5%
return on equity
Free cash margin
up 8%
$28.3M FCF
D/E
0.02
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- generating cash from operations
- profits backed by cash
- reduced long-term debt
Trade setup
ATR%
4.6%
$1.70 a day · 2×ATR $33.75
RS
84 / 99
vs the universe
Trend
6 / 8
150-day under the 200-day, 200-day not rising
Relative volume
0.9×
vs 50-day average
Up/down volume
1.35
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 6 of 8
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.2% over the year, from 28m to 30m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 81.9% to 79.4%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Jul 30, 2026
Financials
- Gross 79%
- Net -7%
- Free cash 8%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $62.6M | $94.1M | $137.0M | $219.8M | $332.1M | $344.2M |
| Gross margin | 85% | 83% | 77% | 80% | 82% | 79% |
| Operating income | -$6.5M | -$40.1M | -$72.9M | -$68.0M | $8.7M | -$42.8M |
| Net income | -$10.3M | -$31.3M | -$67.1M | -$57.5M | $18.2M | -$24.2M |
| Net margin | -16% | -33% | -49% | -26% | 5% | -7% |
| Earnings per share | -$0.54 | -$1.24 | -$2.58 | -$2.14 | $0.62 | -$0.83 |
| Free cash flow | $5.1M | -$22.5M | -$47.3M | -$19.2M | $36.5M | $28.3M |
| Free cash margin | 8% | -24% | -35% | -9% | 11% | 8% |
| Cash | $409.9M | $329.6M | $122.9M | $98.8M | $119.7M | $116.7M |
| Long-term debt | $0 | — | — | $0 | $9.7M | $9.6M |
| Shareholders' equity | $415.7M | $411.7M | $399.1M | $391.3M | $455.8M | $470.9M |
| Shares outstanding | 24.81m | 25.38m | 26.55m | 27.41m | 28.48m | 29.69m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 3, 2025 | Quarterly ↗ | Sep 30, 2025 | 34d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Jul 30, 2026 | Results · Regulation FD ↗ |
| May 29, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results · Regulation FD ↗ |
| Feb 26, 2026 | Results · Regulation FD ↗ |
| Jan 13, 2026 | Results · Regulation FD ↗ |
| Nov 3, 2025 | Results · Regulation FD ↗ |
| Aug 8, 2025 | Charter or bylaws ↗ |
| Aug 4, 2025 | Results · Regulation FD ↗ |
| May 23, 2025 | Holder rights changed · Charter or bylaws · Shareholder vote ↗ |
| May 5, 2025 | Results · Regulation FD ↗ |
| Feb 27, 2025 | Results · Regulation FD ↗ |
| Jan 13, 2025 | Results · Regulation FD ↗ |